Maria E Lindgren

Summary

Affiliation: Stockholm University
Country: Sweden

Publications

  1. ncbi request reprint Cell-penetrating peptides
    M Lindgren
    Department of Neurochemistry and Neurotoxicology, Stockholm University, S 106 91 Stockholm, Sweden
    Trends Pharmacol Sci 21:99-103. 2000
  2. pmc Passage of cell-penetrating peptides across a human epithelial cell layer in vitro
    Maria E Lindgren
    Department of Neurochemistry and Neurotoxicology, Stockholm University, S 106 91 Stockholm, Sweden
    Biochem J 377:69-76. 2004
  3. ncbi request reprint Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide
    Maria Lindgren
    Department of Neurochemistry, The Arrhenius Laboratories for Natural Sciences, Stockholm University, SE 106 91 Stockholm, Sweden
    Biochem Pharmacol 71:416-25. 2006

Detail Information

Publications3

  1. ncbi request reprint Cell-penetrating peptides
    M Lindgren
    Department of Neurochemistry and Neurotoxicology, Stockholm University, S 106 91 Stockholm, Sweden
    Trends Pharmacol Sci 21:99-103. 2000
    ....
  2. pmc Passage of cell-penetrating peptides across a human epithelial cell layer in vitro
    Maria E Lindgren
    Department of Neurochemistry and Neurotoxicology, Stockholm University, S 106 91 Stockholm, Sweden
    Biochem J 377:69-76. 2004
    ..4 kDa fluorescein-labelled dextran was limited. In conclusion, the results indicate that the transportan peptides pass the epithelial cell layer mainly by a mechanism involving a transcellular pathway...
  3. ncbi request reprint Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide
    Maria Lindgren
    Department of Neurochemistry, The Arrhenius Laboratories for Natural Sciences, Stockholm University, SE 106 91 Stockholm, Sweden
    Biochem Pharmacol 71:416-25. 2006
    ..8 and 20 microM, respectively. In summary, cell-penetrating peptide conjugation of MTX is a new way of increasing delivery, and thereby, the potency of already well-characterized therapeutic molecules into drug resistant tumour cells...